Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19

Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200324046850N2

Enrollment

Registered

2020-03-29

Start date

2020-03-18

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. 2019-nCOV disease

Interventions

Intervention 1: lopinavir (50 mg) –ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose + sofosbuvir (400 mg)-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: COVID-19 patients that have positive PCR test of nasopharyngeal sample or have bilateral multi-lobar ground glass opacity in CT scan O2 saturation under 94% or respiratory rate above 24 or decreased level of consciousness

Exclusion criteria

Exclusion criteria: patients under 18 years pregnant or breast feeding women patients did not consent to participate in the study patients who took any complementary medicine safety problem for patients patients with any allergy or hypersensitivity to Sofosbuvir + Daclatasvir or Ribavirin or with major interaction with other medicine

Design outcomes

Primary

Measure	Time frame
Time to clinical improvement defined as start of taking medication time to alive hospital discharge. Timepoint: The beginning of the study , the time of discharge and 21 days after discharge. Method of measurement: Medical record.	—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: Time of discharge. Method of measurement: Number of hospital days.;Duration of stay at ICU. Timepoint: Daily. Method of measurement: Number of days of hospitalization in ICU.;Mortality rate. Timepoint: Daily. Method of measurement: Medical record.;Respiratory rate. Timepoint: Daily. Method of measurement: Count the number of breaths per minute.;Laboratory variables. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Medical record.;Adverse events. Timepoint: Time of discharge. Method of measurement: Medical record.	—

Measure

Time frame

Duration of hospitalization. Timepoint: Time of discharge. Method of measurement: Number of hospital days.;Duration of stay at ICU. Timepoint: Daily. Method of measurement: Number of days of hospitalization in ICU.;Mortality rate. Timepoint: Daily. Method of measurement: Medical record.;Respiratory rate. Timepoint: Daily. Method of measurement: Count the number of breaths per minute.;Laboratory variables. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Medical record.;Adverse events. Timepoint: Time of discharge. Method of measurement: Medical record.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Mobark

Abadan University of Medical Sciences

s.mobarak@abadanums.ac.ir+98 61 5326 7800

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026